semaglutide mash fda approval The has approved Wegovy (semaglutide) as a treatment for metabolic-associated steatohepatitis (MASH) with moderate-to-advanced scarring, a serious liver condition affecting approximately 6% of US adults. Key highlights of drug development program Novo's Wegovy becomes first GLP-1
Pay in 4 interest-free payments of $7.16 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21




















![Physicians Say GLP-1s for Weight Loss are Overprescribed [Survey]](https://cdn.prod.website-files.com/63bc6cdba9784b6ec05f51aa/66aab037edd3ca02bb9085f2_GLP-1%20Provider%20Survey%20-%20Open%20Graph.jpg)






